There are two trials that I think are probably the most excited about. One of them is called the PEAK trial, and it was a ...

Surgery and chemotherapy together improved survival in GIST patients with liver metastases, increasing median cancer-specific ...

NEW YORK, March 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced breakthrough preclinical findings demonstrating the ...

Gastrointestinal stromal tumors (GISTs) represent a rare tumor entity that occurs in the muscular layer of the digestive tract. These tumors commonly metastasize to the liver and peritoneum, and ...

PLYMOUTH, Mass.--(BUSINESS WIRE)--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced updated ...

Kura Oncology, Inc. announced the initiation of the KOMET-015 Phase 1 clinical trial, which will evaluate the safety and effectiveness of ziftomenib, an investigational menin inhibitor, in combination ...

Please provide your email address to receive an email when new articles are posted on . Imatinib interruption resulted in shorter median OS. Interruption also appeared linked to rapid progression and ...

GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK ...

New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 ...